

1 **Usability and acceptability of oral fluid- and blood-based**
2 **hepatitis C virus self-testing among the general population**
3 **and men who have sex with men in Malaysia**

4
5 Huan-Keat Chan¹, Xiaohui Sem², Elena Ivanova^{2*}, Sheela Bai A/P Pannir Selvam³, Narul Aida Salleh⁴, Abdul
6 Hafiz Bin Mohamad Gani⁵, Emmanuel Fajardo², Sonjelle Shilton² and Muhammad Radzi Abu Hassan¹

7
8 ¹Clinical Research Centre, Hospital Sultanah Bahiyah, Alor Setar, Malaysia

9 ²FIND, Geneva, Switzerland

10 ³Cheras Health Clinic, Kuala Lumpur, Malaysia

11 ⁴Kuala Lumpur Health Clinic, Kuala Lumpur, Malaysia

12 ⁵Mahmoodiah Health Clinic, Johor Bharu, Malaysia

13
14 *Corresponding Author:

15 Email: elena.ivanova@finddx.org (EI)

16

17 **Abstract:**

18 Hepatitis C self-testing (HCVST) is emerging as an additional strategy that could help to expand
19 access to HCV testing. We conducted a study to assess the usability and acceptability of two types of
20 HCVST, oral fluid- and blood-based, among the general population and men who have sex with men
21 (MSM) in Malaysia.

22 An observational study was conducted in three primary care centres in Malaysia. Participants who
23 were layman users performed the oral fluid- and blood-based HCVST sequentially. Usability was assessed
24 by calculating the rate of errors observed, the rate of difficulties faced by participants as well as inter-
25 reader (self-test interpreted by self-tester vs interpreted by trained user) and inter-operator
26 concordances (self-test vs test performed by trained user). The acceptability of HCV self-testing was
27 assessed using an interviewer-administered semi-structured questionnaire. Participants were also
28 required to read contrived test results which included “positive”, “negative”, and “invalid”.

29 There was a total of 200 participants (100 general population, 100 MSM; mean age 33.6 ± 14.0
30 years). We found a high acceptability of oral fluid- and blood-based HCVST across both general population
31 and MSM. User errors, related to timekeeping and reading within stipulated time, were common.
32 However, the majority of the participants were still able to obtain and interpret results correctly, including
33 that of contrived results. The high acceptability of HCVST among the participants did not appreciably
34 change after they had experienced both tests, with 97.0% of all participants indicating they would be
35 willing to use HCVST again and 98.5% of them indicating they would recommend it to people they knew.
36 There was no significant difference between the general population and MSM in these aspects.

37 Our study demonstrates that both oral fluid- and blood-based HCVST are highly acceptable among
38 both the general population and MSM. Both populations also showed comparable ability to conduct the

39 tests and interpret the results. Overall, this study suggests that HCVST could be introduced as an addition
40 to existing HCV testing services in Malaysia. Further studies are needed to establish the optimal
41 positioning of self-testing alongside facility-based testing to expand access to HCV diagnosis in the
42 country.

43

44 Keywords: HCV, self-testing, MSM, general population, usability, acceptability

45 Introduction

46 Hepatitis C virus (HCV) infection remains a major contributor to life-threatening liver
47 diseases worldwide. Approximately 58 million individuals are currently living with hepatitis C [1,
48 2]. The advent of highly effective direct-acting antivirals (DAAs), coupled with the World Health
49 Organization's (WHO) goal to eliminate HCV as a public health threat by 2030 [3], has prompted
50 global screening and treatment scale-up efforts.

51 Although 9.4 million HCV-infected individuals benefited from simplified testing
52 procedures and received DAA-based treatment between 2016 and 2021 [4], the suboptimal
53 uptake of facility-based testing, largely due to the poor accessibility of primary care, concerns
54 around stigma, and competing priorities [5, 6], has limited the expansion of treatment. Adopting
55 cost-effective yet user-friendly innovations, particularly self-testing, may help overcome such
56 challenges and make decentralized HCV testing a success [7].

57 Self-testing is a process in which an individual collects a specimen, performs a test and
58 interprets the results on their own [8, 9]. HIV self-testing (HIVST) has been used to complement
59 conventional facility-based HIV testing services [10]. It has been shown to substantially enhance
60 HIV testing uptake, especially among men who have sex with men (MSM) [11, 12]. Given the
61 overlapping risk factors and challenges of HCV and HIV, policy and programme synergies in
62 national responses to these infections have been advocated [13]. Recently, WHO issued a new
63 recommendation to use HCV self-testing (HCVST) as an additional approach to supplement
64 facility-based testing services [14]. It is critical that countries introducing HCVST into their testing

65 policies adapt the WHO's recommendations accordingly to the national and local context and
66 most importantly, solicit community preferences.

67 Malaysia, an upper middle-income country with a population of 32.7 million, has an anti-
68 HCV prevalence of approximately 1.9% in the general population [15] and 4.6% in MSM [16]. The
69 national response to HCV in Malaysia is mainly driven by the Ministry of Health (MOH), based on
70 principles of improving treatment accessibility and resource optimization. Despite initial
71 successes in the expansion of DAA-based treatment [17, 18], a large majority of those infected
72 remain undiagnosed and the MOH continues to collaborate with FIND to explore options
73 increasing access to HCV screening.

74 Recent studies of oral fluid-based HCVST conducted in Egypt, Vietnam and Georgia have
75 shown overall high usability and acceptability [19-21], while blood-based HCVST was shown to
76 have high usability in South Africa (in the general population) [22]. HCV self-testing would also
77 be accepted by the general population in Rwanda and people who inject drugs (PWID) in
78 Kyrgyzstan who had no actual experience of self-testing [23,24]. In this study, we made the first
79 attempt to determine the usability and acceptability of both oral fluid- and blood-based HCVST
80 among the general population and MSM in Malaysia, including understanding how well
81 participants can interpret HCVST and contrived results.

82

83 **Methods**

84 **Study design and setting**

85 This cross-sectional study was undertaken in three public primary care centres located in
86 the State of Johor (Mahmoodiah Health Clinic) and the Federal Territory of Kuala Lumpur (Cheras
87 Health Clinic and Kuala Lumpur Health Clinic). Apart from providing general medical care, these
88 three centres also run special clinics for sexually transmitted diseases (STDs), where
89 approximately 70% of patients are MSM. This study (protocol number: NMRR-20-1794-56098)
90 was approved by the Medical Research Ethics Committee of the MOH.

91

92 **Study participants and sample size**

93 Participants were recruited via convenience sampling during a 2-month period (18
94 December 2020 to 21 February 2021). They were all adults (≥ 18 years of age) who either self-
95 referred to participate in this study or were receiving care at one of the three study sites at the
96 time of being approached. All participants were considered to have an unknown HCV status as
97 they either have never been tested for HCV before or tested negative more than 6 months prior
98 to study enrollment. They also had no experience with either HIVST or HCVST.

99 Based on expert opinion derived from experience with HIVST and the finding of a recent
100 study comparing PWID and MSM when performing HCVST [19], this study was powered to detect
101 a 20% difference in the usability of HCVST between the general population and MSM (70% versus
102 50%). The level of significance (α) and power ($1-\beta$) was fixed at 5% and 80%, and the minimum
103 sample sizes required for the general population and MSM were therefore 94 individuals each.
104 Assuming a 5% attrition rate, a sample-size target of 100 participants per group was set.

105 **HCV self-testing kits**

106 All participants performed HCVST with two kits: OraQuick® (oral fluid-based test kit;
107 manufactured by OraSure Technologies, United States of America) and First Response® (blood-
108 based test kit; manufactured by Premier Medical Corporation, India). OraQuick® (sensitivity:
109 98.1%; specificity: 99.6%) was already prequalified by the WHO for professional use at the time
110 of this study, whereas First Response® (sensitivity: 100%; specificity: 100%) was still under the
111 review of the WHO for professional use. Both kits were repackaged and adapted for HCVST by
112 the manufacturers and labelled “for research use only”. Instructions for use (IFU) in both Bahasa
113 Malaysia and English were also included in the package. No results from either test were used to
114 guide any clinical decisions. All participants received a standard HCV test at the end of the study
115 and were linked to treatment if necessary.

116

117 **Study procedures**

118 At the study sites, individuals were briefed about the study and screened for eligibility.
119 After providing written consent, study procedures were carried out in a private room. A
120 structured questionnaire was used to record their demographic data, past exposure to HCV risk
121 factors, experience with HCV and HIV testing, and willingness to use HCVST. Participants were
122 then provided with both written (in Bahasa Malaysia or English) and pictorial instructions about
123 HCVST.

124 To reduce usability bias, half of the participants at each study site performed the oral
125 fluid-based test first, while the remainder used the blood-based test first. Participants were
126 advised to avoid consuming food or using oral care products for 15 and 30 minutes, respectively,
127 before performing the oral fluid-based test. For the oral fluid-based test, participants swabbed
128 their upper and lower gums with the test device, placed it in the provided tube, and read the
129 results within 20 to 40 minutes of taking the test. For the blood-based test, participants collected
130 a drop of blood by pricking a finger with a lancet, transferred the blood onto the test device,
131 added the diluent, and read the results after 15 minutes. Any errors observed during self-testing
132 and result interpretation by the participant were documented by a study team member using a
133 checklist. No assistance was provided unless requested by a participant and after at least 15
134 minutes of repeated efforts to conduct each testing step unassisted.

135 To determine inter-reader concordance, a second study team member, who was blinded
136 to the self-reported test results, re-read the results within the stipulated time. Subsequently, to
137 determine inter-operator concordance, a third study team member, who was blinded to both the
138 self-reported and re-read results, performed professional-use oral fluid- and blood-based tests.
139 Next, participants were required to read contrived test results which included a mix of “positive”,
140 “negative”, and “invalid” results (S1 Fig). Finally, a structured interview was conducted to explore
141 the acceptability of HCVST among participants, as well as to collect additional information
142 regarding their awareness of HCV and its treatment.

143 **Data assessment and analysis**

144 The usability of HCVST was expressed as the proportions of participants who were
145 observed to make mistakes, incorrectly interpret results, experience difficulties or require
146 assistance when performing the tests. The inter-reader and inter-operator concordances of result
147 interpretation represented the degrees (in percentages) to which the test results reported by the
148 participants agreed with those re-read and found in the repeated tests, respectively. The Gwet's
149 AC1 coefficient was also used to measure the inter-reader and inter-operator reliability of result
150 interpretation, given the imbalanced distribution of HCV test results across categories [25].
151 Acceptability of HCVST among the participants, along with their awareness of hepatitis C and its
152 treatment, were summarized as numbers and percentages. Pearson's chi-square or Fisher's exact
153 test was used to explore associations between two categorical variables, while the Mann-
154 Whitney U test was used to compare means between two groups of participants. Statistical
155 analyses were performed using SPSS Statistics V21.0 (IBM, New York), with the level of
156 significance set at $p < 0.05$.

157

158 **Results**

159 **Recruitment and characteristics of participants**

160 Of 221 individuals approached, 216 (97.7%) fulfilled the eligibility criteria and 200 (92.6%)
161 consented to participate in this study. The number of participants recruited in the three study
162 sites was 60 (30.0%), 66 (33.0%) and 74 (37.0%) respectively. All participants completed both oral
163 fluid- and blood-based HCVST, as well as the post-testing interviews (Fig 1).

164 Fig 1. **Flowchart of participant enrolment.** GP, general population; HCVST, hepatitis C self-
165 testing; MSM, men who have sex with men.

166 Table 1 shows the participants' self-reported characteristics; their mean age was $33.6 \pm$
167 14.0 years; most were male (75.0%) and unmarried (65.0%). MSM were more likely to make >1
168 visit to clinics annually compared with the general population (80.0% vs. 39.0%, $p < 0.001$).
169 Majority of the MSM participants have been previously tested for HIV (96.0% vs 50%, $p < 0.001$);
170 59% of them reported a positive HIV test result. Although none of the participants had prior
171 experience with HIV or HCV self-testing, participants from the general population had more
172 experience with performing home-based testing such as pregnancy, glucose monitoring and
173 blood pressure tests (43.0% vs. 16%; $p < 0.001$). Before taking the self-test, 83.0% of the
174 participants across both population groups were aware of self-testing approaches in general and
175 almost all the participants (98.0%) expressed their willingness to use HCVST if it was available.

176

177 **Table 1:** Self-reported characteristics of participants: overall, general population and men who
 178 have sex with men.

Characteristics	Overall (n = 200)	Subgroup		p-value
		GP (n = 100)	MSM (n = 100)	
Age, median (IQR)	33.6 (14.0)	35.8 (19.0)	29.5 (11.0)	0.121 ^a
Sex, n (%)				
Male	157 (78.5)	57 (57.0)	100 (100.0)	-
Female	43 (21.5)	43 (43.0)	-	
Education level, n (%)				
Tertiary	104 (52.0)	45 (45.0)	59 (59.0)	0.123 ^b
Secondary/post-secondary	90 (45.0)	51 (51.0)	39 (39.0)	
No formal education/primary	6 (0.3)	4 (4.0)	2 (2.0)	
Work status, n (%)				
Employed/self-employed	163 (81.5)	75 (75.0)	88 (88.0)	0.018^c
Unemployed	37 (18.5)	25 (25.0)	12 (12.0)	
Marital status, n (%)				
Unmarried	130 (65.0)	39 (39.0)	91 (91.0)	<0.001^b
Married or living with a partner	61 (30.5)	54 (54.0)	7 (7.0)	
Divorced, separated or widowed	9 (4.5)	7 (7.0)	2 (2.0)	
History of exposure to HCV risk factors, n (%)				
Condomless anal intercourse	80 (40.0)	-	80 (80.0)	-
Dental procedure	72 (36.0)	42 (42.0)	30 (30.0)	0.077 ^c
Surgical procedure	38 (19.0)	23 (23.0)	15 (15.0)	0.149 ^c
Sharing shaving tool or toothbrush	14 (7.0)	5 (5.0)	9 (9.0)	0.268 ^c
Having a tattoo	4 (2.0)	1 (1.0)	3 (3.0)	0.621 ^b
Injecting non-prescription drugs	2 (1.0)	0 (0.0)	2 (2.0)	0.497 ^b
Frequency of clinic visit, n (%)				
>1 time per year	119 (59.5)	39 (39.0)	80 (80.0)	<0.001^b
1 time per year	42 (21.0)	27 (27.0)	15 (15.0)	
Rarely	33 (16.5)	29 (29.0)	4 (4.0)	
Never	6 (3.0)	5 (5.0)	1 (1.0)	
Latest HCV test result, n (%)				
Negative	42 (21.0)	9 (9.0)	33 (33.0)	<0.001^c
Never tested	158 (79.0)	91 (91.0)	67 (67.0)	
Latest HIV test result, n (%)				
Positive	60 (30.0)	1 (1.0)	59 (59.0)	<0.001^b
Negative	86 (43.0)	49 (49.0)	37 (37.0)	
Never tested	54 (27.0)	50 (50.0)	4 (4.0)	
Aware that at least one type of home-based self-testing approach is available, n (%)	166 (83.0)	87 (87.0)	79 (79.0)	0.132 ^c
Has experience with performing any home-based self-testing, n (%)	59 (29.5)	43 (43.0)	16 (16.0)	<0.001^c
Willing to use home-based HCV self-testing if it is made available^d	196 (98.0)	98 (98.0)	98 (98.0)	>0.95 ^b

179 HCV, hepatitis C virus; GP, general population; HIV, human immunodeficiency virus; IQR, interquartile range; MSM, men who
 180 have sex with men.

181 ^a Mann–Whitney U test; ^b Fisher’s exact test; ^c Pearson’s chi-square test; ^d Asked before performing HCVST.

182

183 Usability of HCVST

184 For the oral fluid-based HCVST, 53.0% of the participants completed the self-test
185 procedure without any error. The most common mistakes observed during the pre-testing steps
186 were not practicing proper timekeeping (24.5%) and not reading the test results within the
187 stipulated time (38.5%). Excluding these two mistakes, 87.5% of the participants completed the
188 self-test procedure without any error. In addition, 88.5% of the participants completed the self-
189 test procedure without any difficulty and 95.5% completed the self-test procedure without any
190 assistance. The general population and MSM did not differ in any of the above aspects of oral
191 fluid-based HCVST (Table 2). In terms of the blood-based HCVST, 28.0% of the participants
192 completed the self-test procedure without any error. The most common mistakes observed
193 during the pre-testing steps were not washing hands in warm water and drying them before
194 performing the test (58.0%); not waiting long enough (15 minutes after adding the diluent) to
195 read the test results (44.0%); not choosing a middle or ring finger to prick for the test (43.5%);
196 not practicing correct timekeeping (35.0%); not discarding the first drop and using the second
197 drop of blood for the test (22.0%); and not massaging and warming the finger before the test
198 (20.0%). Despite these errors, 62.5% of the participants completed the self-test procedure
199 without any difficulty and 87.5% completed the self-test procedure without any assistance.
200 Compared with the general population, MSM were less likely to experience difficulties (6.0% vs.
201 16.0%; $p = 0.024$) and make errors (1.0% vs. 11.0%; $p = 0.003$) when pricking their fingers with a
202 lancet (Table 3).

203

204 **Table 2:** Assessment of mistakes, difficulties and assistance required in oral fluid-based self-
 205 testing: overall, general population and men who have sex with men.

Step	Overall (n = 200)	Subgroup		p-value
		GP (n = 100)	MSM (n = 100)	
No. of participants who made errors in pre-testing steps, n (%)				
Opening the package	0 (0.0)	0 (0.0)	0 (0.0)	-
Reading and using the instructions for use	0 (0.0)	0 (0.0)	0 (0.0)	-
Removing the test tube from the test pack	0 (0.0)	0 (0.0)	0 (0.0)	-
Removing the cap from the test tube	0 (0.0)	0 (0.0)	0 (0.0)	-
Placing the tube into the stand	3 (1.5)	0 (0.0)	3 (3.0)	0.246 ^a
Removing the test device from the test pack	0 (0.0)	0 (0.0)	0 (0.0)	-
No. of participants who made errors in testing steps, n (%)				
Avoidance of touching the flat pad	12 (6.0)	7 (7.0)	5 (5.0)	0.522 ^b
Collecting oral fluid	14 (7.0)	4 (4.0)	10 (10.0)	0.096 ^b
Placing of test device in the tube	2 (1.0)	0 (0.0)	2 (2.0)	0.497 ^a
Timekeeping	49 (24.5)	28 (28.0)	21 (21.0)	0.250 ^b
Reading results within 20–40 minutes after the test	77 (38.5)	41 (41.0)	36 (36.0)	0.467 ^b
No. of participants who made at least one error, n (%)	94 (47.0)	47 (47.0)	47 (47.0)	>0.95 ^b
No. of participants who made at least one error (excluding those related to timekeeping and reading results within stipulated time), n (%)	25 (12.5)	11 (11.0)	14 (14.0)	0.521 ^b
No. of participants with the following observed difficulty, n (%)				
Opening the package	2 (1.0)	2 (2.0)	0 (0.0)	0.497 ^a
Opening the test tube	5 (2.5)	5 (5.0)	0 (0.0)	0.059 ^a
Sliding the tube into the stand	13 (6.5)	4 (4.0)	9 (9.0)	0.152 ^b
Placing the test device into the tube	2 (1.0)	0 (0.0)	2 (2.0)	0.497 ^a
Reading and interpreting the results	3 (1.5)	1 (1.0)	2 (2.0)	>0.95 ^a
No. of participants with observed difficulties for at least one step, n (%)	23 (11.5)	12 (12.0)	11 (11.0)	0.825 ^b
No. of participants requiring assistance, n (%)				
Opening the package	0 (0.0)	0 (0.0)	0 (0.0)	-
Opening the test tube	2 (1.0)	1 (1.0)	1 (1.0)	>0.95 ^a
Sliding the tube into the stand	7 (3.5)	2 (2.0)	5 (5.0)	0.445 ^a
Placing the test device into the tube	1 (0.5)	0 (0.0)	1 (1.0)	>0.95 ^a
Reading the results	0 (0.0)	0 (0.0)	0 (0.0)	-
No. of participants requiring assistance for at least one step, n (%)	9 (4.5)	3 (3.0)	6 (6.0)	0.498 ^a

206 GP, general population; MSM, men who have sex with men.

207 ^a Fisher's exact test;

208 ^b Pearson's chi-square test

209

211 **Table 3:** Assessment of mistakes, difficulties and assistance required in blood-based self-testing:
 212 overall, general population and men who have sex with men.

Step	Overall (n = 200)	Subgroup		
		GP (n = 100)	MSM (n = 100)	p-value
No. of participants who made errors in pre-testing steps, n (%)				
Opening the package	0 (0.0)	0 (0.0)	0 (0.0)	-
Reading and using the instructions for use	1 (0.5)	0 (0.0)	1 (1.0)	>0.95 ^a
Removing the test device from the foil pouch	0 (0.0)	0 (0.0)	0 (0.0)	-
Washing hands in warm water and drying them	116 (58.0)	61 (61.0)	55 (55.0)	0.390 ^b
Choosing a middle or ring finger	87 (43.5)	43 (43.0)	44 (44.0)	0.887 ^b
Massaging and warming the finger	40 (20.0)	20 (20.0)	20 (20.0)	>0.95 ^b
Cleaning fingertip with alcohol pad	3 (1.5)	2 (2.0)	1 (1.0)	>0.95 ^a
No. of participants who made errors in testing steps, n (%)				
Pressing the lancet against the finger to prick skin	12 (6.0)	11 (11.0)	1 (1.0)	0.003 ^b
Wiping away the first drop of blood and rubbing to create a second	44 (22.0)	23 (23.0)	21 (21.0)	0.733 ^b
Using the transfer device to collect the drop of blood	8 (8.0)	3 (3.0)	5 (5.0)	0.721 ^a
Dispensing the whole blood into the round specimen well	2 (1.0)	2 (2.0)	0 (0.0)	0.497 ^a
Applying the plaster	25 (12.5)	11 (11.0)	14 (14.0)	0.521 ^b
Twisting and pulling the cap to open assay diluent, then dispensing two drops of the assay diluent into the specimen well	14 (7.0)	4 (4.0)	10 (10.0)	0.096 ^b
Timekeeping	70 (35.0)	38 (38.0)	32 (32.0)	0.374 ^b
Reading the results 15 minutes after adding the diluent	88 (44.0)	47 (47.0)	41 (41.0)	0.393 ^b
No. of participants who made at least one error, n (%)	144 (72.0)	74 (74.0)	70 (70.0)	0.529 ^b
No. of participants who made at least one error (excluding timekeeping and reading results within stipulated time), n (%)	145 (72.5)	74 (74.0)	71 (71.0)	0.635 ^b
No. of participants with the following observed difficulty, n (%)				
Opening the package	0 (0.0)	0 (0.0)	0 (0.0)	-
Pricking a finger	22 (11.0)	16 (16.0)	6 (6.0)	0.024 ^b
Obtaining a blood drop	23 (11.5)	13 (13.0)	10 (10.0)	0.506 ^b
Collecting the blood drop with the transfer device	54 (27.0)	26 (26.0)	28 (28.0)	0.750 ^b
Dispensing the diluent on the specimen well	5 (2.5)	3 (3.0)	2 (2.0)	>0.95 ^a
Reading the results	1 (0.5)	1 (1.0)	0 (0.0)	>0.95 ^a
No. of participants with observed difficulties for at least one step, n (%)	75 (37.5)	41 (41.0)	34 (34.0)	0.307 ^b
No. of participants requiring assistance, n (%)				
Opening the package	0 (0.0)	0 (0.0)	0 (0.0)	-
Obtaining a blood drop	1 (0.5)	1 (1.0)	0 (0.0)	>0.95 ^a
Transferring the blood drop to the device	10 (5.0)	5 (5.0)	5 (5.0)	>0.95 ^b
Dispensing the diluent onto the sample well	4 (2.0)	1 (1.0)	3 (3.0)	0.621 ^a
Reading the results	0 (0.0)	0 (0.0)	0 (0.0)	-
No. of participants requiring assistance for at least one step, n (%)	25 (12.5)	15 (15.0)	10 (10.0)	0.285 ^b

213 GP, general population; MSM, men who have sex with men.

214 ^a Fisher's exact test;

215 ^b Pearson's chi-square test

216

217

218 **HCVST result interpretation**

219 In this study, no positive result was detected by trained study staff re-reading the self-
220 test nor by trained study staff administering a professional test. For both the oral fluid-based and
221 blood-based HCVST, there were high inter-reader concordances among the general population
222 and MSM groups at 97.0% vs 99.0% and 99.0% vs 98.0% respectively (Table 4). The Gwet's AC1
223 coefficients were 0.76 and 0.98 for the oral fluid-based HCVST among the general population and
224 MSM, respectively, while they were 0.98 and 0.60 for the blood-based HCVST among the general
225 population and MSM, respectively. Inconsistent result interpretation between readers was
226 documented in four cases of oral fluid-based testing (three participants from the general
227 population read their negative results as positive or invalid, while one MSM read their invalid
228 result as negative) and in three cases of blood-based testing (one participant from the general
229 population read their invalid result as negative, while two MSM read their negative results as
230 positive or invalid).

231

232 **Table 4:** Assessment of inter-reader and inter-operator agreement in test result interpretation.

Participant interpretation	Inter-reader concordance (re-read by trained staff)				Inter-operator concordance (re-tested by trained staff)			
	Positive	Negative	Invalid	Total	Positive	Negative	Invalid	Total
Oral fluid-based test in GP (n = 100)								
Positive	0	1	0	1	0	1	0	1
Negative	0	90	0	90	0	90	0	90
Invalid	0	2	7	9	0	8	1	9
Total	0	93	7	100	0	99	1	100
Invalid rate (%)	7.0				1.0			
Concordance (%)	97.0				91.0			
Gwet's AC1 coefficient	0.76				0.89			
Oral fluid-based test in MSM (n = 100)								
Positive	0	0	0	0	0	0	0	0
Negative	0	97	1	98	0	98	0	98
Invalid	0	0	2	2	0	2	0	2
Total	0	97	3	100	0	100	0	100
Invalid rate (%)	3.0				0.0			
Concordance (%)	99.0				98.0			
Gwet's AC1 coefficient	0.98				0.99			
Blood-based test in GP (n = 100)								
Positive	0	0	0	0	0	0	0	0
Negative	0	96	1	97	0	97	0	97
Invalid	0	0	3	3	0	3	0	3
Total	0	96	4	100	0	100	0	100
Invalid rate (%)	4.0				0.0			
Concordance (%)	99.0				97.0			
Gwet's AC1 coefficient	0.98				0.99			
Blood-based test in MSM (n = 100)								
Positive	0	1	0	1	0	1	0	1
Negative	0	96	0	96	0	96	0	96
Invalid	0	1	2	3	0	3	0	3
Total	0	98	2	100	0	100	0	100
Invalid rate (%)	2.0				0.0			
Concordance (%)	98.0				96.0			
Gwet's AC1 coefficient	0.60				0.99			

233 GP, general population; MSM, men who have sex with men.

234

235 The inter-operator concordances for the oral fluid-based HCVST were 91.0% and 98.0%
236 among the general population and MSM, respectively; for the blood-based HCVST, the inter-
237 operator concordances were 97.0% and 96.0% among the general population and MSM,
238 respectively. The Gwet's AC1 coefficients were 0.89 and 0.99 for the oral fluid-based HCVST
239 among the general population and MSM, respectively, while they were 0.99 and 0.99 for the
240 blood-based HCVST among the general population and MSM, respectively. The results obtained
241 from the professional-use tests conducted by trained users were different from those reported
242 by the participants in eleven and seven cases of oral fluid- and blood-based tests, respectively.
243 Among the eleven discordant cases involving oral fluid-based HCVST, one participant in the
244 general population who interpreted their result as positive, was negative when retested by a
245 trained user, while eight and two participants among the general population and MSM,
246 respectively and who interpreted their results as invalid, were all negative on retesting. Among
247 the seven discordant cases involving blood-based HCVST, one MSM participant, who interpreted
248 their result as positive, was negative when retested by a trained user, while three participants in
249 each of the general population and MSM groups and who interpreted their results as invalid,
250 were all negative on retesting.

251 Participants were generally able to read positive, negative, and invalid contrived results
252 for both the oral fluid- and blood-based tests (Table 5). Accuracy of result interpretation was
253 similar across both study populations and types of HCVST. Overall, majority of the contrived test
254 results were interpreted correctly. Positive results with a clear test line and negative results were
255 most accurately interpreted by the participants with over 97% of correct interpretations. Weak
256 positives with faint test line and invalid results with test line only posed some difficulties for

257 interpretation. Contrived oral fluid HCVST devices displaying invalid test line-only results were
 258 read correctly by 62.5% of the participants, while similar blood-based HCVST devices were read
 259 correctly by 78.5% of the participants. Weak positive results with a clear control and a faint test
 260 line were least accurately interpreted by the participants (51.3% for blood-based HCVST and 64%
 261 for oral fluid-based HCVST).

262 **Table 5:** Assessment of accuracy in the interpretation of test results based on contrived tests.

Test result	Correct interpretation, n (%)							
	Oral fluid-based test				Blood-based test			
	Overall (n = 200)	GP (n = 100)	MSM (n = 100)	p-value	Overall (n = 200)	GP (n = 100)	MSM (n = 100)	p-value
Positive (with clear control and test lines)	196 (98.0)	98 (98.0)	98 (98.0)	>0.95 ^a	193 (97.5)	98 (98.0)	97 (97.0)	>0.95 ^a
Weak positive (with a clear control line and a faint test line)	128 (64.0)	60 (60.0)	68 (68.0)	0.239 ^b	103 (51.3)	50 (50.0)	53 (53.0)	0.671 ^b
Negative (with only a clear control line)	194 (97.0)	97 (97.0)	97 (97.0)	>0.95 ^a	195 (97.5)	98 (98.0)	97 (97.0)	>0.95 ^a
Invalid (without either control or test lines)	191 (95.5)	96 (96.0)	95 (95.0)	>0.95 ^a	192 (96.0)	97 (97.0)	95 (95.0)	0.721 ^a
Invalid (with only a clear test line)	125 (62.5)	63 (63.0)	62 (62.0)	0.884 ^b	157 (78.5)	81 (81.0)	76 (76.0)	0.389 ^b
TOTAL	834 (83.4)	414 (82.8)	420 (84.0)	0.610^b	840 (84.0)	424 (84.8)	418 (83.6)	0.603^b

263 GP, general population; MSM, men who have sex with men.

264 ^a Fisher's exact test;

265 ^b Pearson's chi-square test.

266 **Acceptability of HCVST**

267 The acceptability of HCVST among the participants did not appreciably change after they
268 had experienced both types of tests (Table 6). Although more than half (52.5%) of all participants
269 were unaware of hepatitis C treatment and its availability in their communities, 97.0% of them
270 expressed their willingness to use HCVST again and 98.5% would recommend it to their family
271 and friends. The participants also expressed a preference to perform HCV self-testing in a primary
272 care centre (33.5%), by themselves at home (20.0%), or by health staff in a primary care centre
273 (20.0%). Just over half (51.5%) of all participants preferred oral fluid- over blood-based HCVST.
274 The main reasons given for preferring the oral fluid-based test, as captured by an open-ended
275 question, were its pain-free nature and ease of use. Nevertheless, 22.5% of participants did not
276 express a preference. The two groups of participants did not differ in their views of HCVST, except
277 that MSM were less willing to take the test kits home to their family and friends (76.0% vs. 88.0%;
278 $p = 0.045$). The main reasons MSM gave for being unwilling to bring the test kits home to their
279 family and friends, as captured by an open-ended question, were a lack of knowledge and
280 confidence to explain the tests.

281

282 **Table 6:** Acceptability of HCVST and additional information regarding awareness of HCV and its
 283 treatment.

Aspect	Overall (n = 200)	Subgroup		p-value
		GP (n = 100)	MSM (n = 100)	
Willing to use HCVST again, n (%)	194 (97.0)	98 (98.0)	96 (96.0)	0.407 ^a
Willing to recommend the test to family and friends, n (%)	197 (98.5)	99 (99.0)	98 (98.0)	>0.95 ^b
Willing to take the test kits to family and friends, n (%)	164 (82.0)	88 (88.0)	76 (76.0) ^c	0.045^a
Preferred HCV testing approach, n (%)				
By oneself in a primary care centre	67 (33.5)	29 (29.0)	38 (38.0)	0.532 ^a
By oneself at home	40 (20.0)	24 (24.0)	16 (16.0)	
By health staff in a primary care centre	40 (20.0)	20 (20.0)	20 (20.0)	
During a regular check-up in a health facility	14 (7.0)	6 (6.0)	8 (8.0)	
During a screening campaign	4 (2.0)	3 (3.0)	1 (1.0)	
No specific preference	35 (35.0)	18 (18.0)	17 (17.0)	
Preferred HCVST type, n (%)				
Oral fluid-based	103 (51.5) ^d	59 (59.0)	44 (44.0)	0.097 ^a
Blood-based	52 (26.0)	21 (21.0)	31 (31.0)	
No specific preference	45 (22.5)	20 (20.0)	25 (25.0)	
Will contact the health facility if HCVST result is positive, n (%)	163 (81.5)	82 (82.0)	81 (81.0)	0.856 ^a
Will take a confirmatory test if HCVST result is positive, n (%)	68 (34.0)	28 (28.0)	40 (40.0)	0.073 ^a
Awareness about hepatitis C treatment, n (%)				
Aware that there is treatment and cure	71 (35.5)	32 (32.0)	39 (39.0)	0.561 ^a
Aware that there is treatment but unsure of cure	24 (12.0)	12 (12.0)	12 (12.0)	
Unaware that there is treatment and cure	105 (52.5)	56 (56.0)	49 (49.0)	
Awareness about availability of hepatitis C treatment in one's community, n (%)				
Available	122 (61.0)	62 (62.0)	60 (60.0)	0.616 ^b
Available but not nearby	6 (3.0)	4 (4.0)	2 (2.0)	
Not available or not sure	72 (36.0)	34 (34.0)	38 (38.0)	

284 GP, general population; HCVST, hepatitis C virus self-testing; MSM, men who have sex with men.

285 ^a Pearson's chi-square test;

286 ^b Fisher's exact test;

287 ^c Main reasons for the unwillingness among MSM to bring the test kits to their family and friends, as captured in an open-ended
 288 question, were a lack of knowledge and confidence to explain the tests;

289 ^d Main reasons for preferring the oral fluid-based test, as captured in an open-ended question, were its pain-free nature and ease
 290 of use.

291

292 Discussion

293 To the best of our knowledge, this study is the first one to report the usability and
294 acceptability of oral fluid- and blood-based HCVST in two populations in a country. By targeting
295 both the general population and MSM, this study has also provided insights into the usability of
296 HCVST among individuals at different levels of risk for HCV infection in Malaysia. The world is
297 currently witnessing an expanding epidemic of sexually transmitted HCV among MSM [26, 27];
298 this study demonstrates that HCVST is a highly acceptable testing modality among MSM in a
299 religiously and culturally conservative society such as Malaysia and hence has a high potential to
300 enhance screening coverage in this high-risk population. Using HCVST in addition and as a
301 complement to HCV testing services in primary care centres also represents another milestone
302 for Malaysia, which has a relatively low prevalence of HCV in the general population [15, 28] and
303 is seeking to micro-eliminate HCV by targeting specific populations [17, 18, 29, 30].

304 Our findings showed that for both HCVST types, the most common mistakes made by
305 participants in this study were not practicing good timekeeping and not reading the results within
306 the stipulated time period (participants tended to read the results once the specimen moved
307 across the result window or once the control line appeared). These critical steps could affect the
308 sensitivity of a HCVST, leading to invalid results or false negatives. In our study, we observed 2
309 out of the 3 invalid results reported by participants were read by them prematurely – just after
310 the specimen moved across the result window – and both turned to be negative when re-read
311 by the trained study staff. We could not assess the likelihood of false negative results as we had
312 no HCV positive cases in our study population, however, reading results before stipulated time

313 could cause false negative results and should this user error persist, it could be a major issue
314 during scale-up of HCVST. The study was conducted before a massive roll out of rapid testing for
315 COVID-19 and it is possible that participants in Malaysia at the time were not sensitized to the
316 use of rapid diagnostic tests (RDTs) and might be unaware of the importance of timekeeping
317 when using RDTs. These mistakes were not observed in Egypt or Vietnam where RDTs have been
318 widely used for screening and diagnosis of infectious diseases [18, 19]. Henceforth the usability
319 in Malaysia might gradually improve as the population gets more familiar with the use of RDTs
320 for self-testing. Such mistakes could also be attributed to unclear instructions in the IFU and
321 might be prevented by further optimizing the IFU and providing supplementary material such as
322 video instructions and flyers. The use of a smartphone application with timer function during
323 HCVST may also guide users to perform these critical steps accurately. While pictorial instructions
324 have shown great potential elsewhere to overcome cultural barriers in promoting self-testing
325 [31], our findings highlight the importance of improving the pictorial instructions in relation to
326 timekeeping and reading the results within the stipulated time period before any scale-up of
327 HCVST. Additionally, the enrolled participants might have overlooked these two aspects as they
328 could be in a hurry to complete the study procedures. Earlier on, they have spent some significant
329 time in the primary care centres for standard of care before undergoing the study procedures
330 and could have wanted to return to work or school as soon as they could. In the near future,
331 when HCVST is made available outside this study and when individuals can conduct HCVST in
332 their home or at a preferred location, these mistakes might be significantly reduced.

333 Another very frequent error observed during the blood-based HCVST was skipping hand
334 washing step recommended prior to sampling. However, this error was considered less critical as

335 it is unlikely to lead to invalid or false results, as indicated by an invalid rate of 2.0 – 4.0% and an
336 inter-operator agreement of more than 96.0%. A further challenge with the blood-based HCVST
337 was the need to obtain and transfer a blood sample, as 27.0% of all participants made mistakes
338 transferring the blood drop to the test device. With regards to additional help provided to
339 participants while they performed the two types of HCVST, transferring the blood drop to the
340 test device required the highest degree of assistance (5.0%). This observation is consistent with
341 an earlier study that reported challenges with specimen collection for blood-based HIVST [32].
342 Again, it is possible that errors in blood-based HCVST procedures were made as participants in
343 Malaysia were not yet sensitized to the use of RDTs and would reduce over time. Consistent to
344 this assumption, we observed that MSM generally experienced fewer difficulties than the general
345 population when pricking their fingers to obtain blood, likely due to their past exposure to RDTs
346 administered by healthcare workers or community workers for HIV or HCV. Difficulties in
347 obtaining blood and handling the test device could discourage new self-testers; therefore,
348 product refinement and simplified testing procedures are necessary [33]. More guidance on
349 specimen collection, such as video-based demonstration [34], is warranted, especially if blood-
350 based HCVST were to be extended to the general population.

351 . Consistent with findings among MSM in Vietnam and Egypt [18, 19], our study indicated
352 high inter-reader concordances and reliability in the interpretation of results for both oral fluid-
353 and blood-based HCVST. Furthermore, the ability of the participants to differentiate between
354 clear “positive”, “negative”, and “invalid” test results was evidenced by their correct
355 interpretation of contrived test results. We observed some difficulties in interpreting weak

356 positive results with a faint test line indicating to a need for additional guidance on how to
357 interpret such results.

358 Consistent with findings from Egypt and Vietnam [19, 20], the participants expressed a
359 strong willingness to use HCVST again and to recommend it to their family and friends. They also
360 expressed a clear preference for oral fluid- over blood-based testing, as did the general
361 population in Rwanda and PWID in Kyrgyzstan who had no actual experience of self-testing
362 [23,24]. In our study, the participants from both groups reported a preference for oral fluid-based
363 HCVST that can be attributed to its ease of use and pain-free nature, which were also reasons for
364 the high acceptability of oral fluid-based HIVST [11, 12]. However, it is worth noting that for
365 HIVST, studies have reported a greater preference for blood- over oral fluid-based self-tests [35,
366 36]. Only one-fifth of participants in our study preferred to perform HCVST by themselves at
367 home. This may imply that they lacked confidence to perform the test alone by themselves at the
368 time of the study, despite the written and pictorial instructions provided. A lack of knowledge
369 and confidence to explain the self-test, as reported in responses to an open-ended question
370 administered during this study, and the possible complication of punitive laws and discrimination
371 against sexual minorities in Malaysia [37, 38], may also have contributed to the reduced
372 willingness of MSM to take the test kits to family and friends. Together, these findings justify
373 continuous efforts to optimize self-testing products, improve IFU, and establish a non-
374 discriminatory hepatitis C care model, as recommended by the WHO [14].

375 The major limitation of this study lies in its focus on individuals who were willing to seek
376 care, had access to health facilities and were enrolled based on their willingness to try HCVST.
377 The structured questionnaires were limited in scope and could not fully capture participants'

378 perceptions of the self-testing experience and acceptability of the self-tests. The usability and
379 acceptability of HCVST among hard-to-reach populations, such as those who live in rural areas
380 and are concerned about stigma, remain unclear. Furthermore, the absence of positive HCV test
381 results among the participants limited the assessment of the inter-operator reliability of HCVST.

382 The MOH, in collaboration with the Malaysian AIDS Council and FIND, has recently
383 initiated another study to address these limitations, mainly through the use of a web-based
384 platform and online distribution to reach out to more potential self-testers [39]. While self-
385 testers with a positive HCV result are expected to present themselves for further care, the MOH
386 also recognizes the need to enhance public awareness of hepatitis C and the availability of
387 curative treatment in health facilities across the country.

388

389 **Conclusion**

390 This study demonstrated that both oral fluid- and blood-based HCVST were highly
391 acceptable among both the general population and MSM in Malaysia. The general population
392 and MSM showed comparable ability to conduct the tests and interpret the results. However,
393 the frequencies of making critical errors related to timekeeping and reading results within
394 stipulated time period were very high. Overall, this study suggests that both oral fluid- and blood-
395 based HCVST could be introduced as an addition to existing HCV testing services for populations
396 at different levels of risk for HCV infection in Malaysia, provided that sufficient guidance and
397 clearer IFU (particularly highlighting the need for proper timekeeping and reading within the
398 stipulated time) are in place.

399 **Acknowledgements**

400 The authors would like to thank the Government of Netherlands for the support; study
401 participants for their involvement; MOH study teams for the implementation of this study; the
402 following civil society organizations for their support in the recruitment of participants - PT
403 Foundation and Intan Life Zone Welfare Society; OraSure Technologies, United States of America,
404 and Premier Medical Corporation, India, for the in-kind contribution of research-use only HCV
405 self-test kits for this study. The authors would also like to thank Cheryl Johnson, Mohammed
406 Jamil, Niklas Luhmann and Philippa Easterbrook for their contributions in conceptualizing and
407 developing protocols for the HCVST evaluation studies; and the Director-General of Health,
408 Malaysia, for his support throughout the conduct of this study and permission to publish the
409 findings.

410 Editorial support, under the direction of the authors and funded by FIND, was provided
411 by Adam Bodley.

412

413 **References**

- 414 1. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. World
415 Health Organization; 2021.
- 416 2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus
417 infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology*. 2013;57(4):1333-
418 42.

- 419 3. Global Health Sector Strategy on Viral Hepatitis 2016–2021: Towards Ending Viral Hepatitis. World
420 Health Organization; 2016.
- 421 4. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis c virus
422 infection. World Health Organization; 2018.
- 423 5. Guidelines on Hepatitis B and C testing. World Health Organization; 2017.
- 424 6. Easterbrook PJ, Group WHOGD. Who to test and how to test for chronic hepatitis C infection -
425 2016 WHO testing guidance for low- and middle-income countries. *J Hepatol.* 2016;65(1 Suppl):S46-S66.
- 426 7. Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators
427 of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. *Harm Reduct*
428 *J.* 2014;11:1.
- 429 8. Peeling RW, Boeras DI, Marinucci F, Easterbrook P. The future of viral hepatitis testing:
430 innovations in testing technologies and approaches. *BMC Infect Dis.* 2017;17(Suppl 1):699.
- 431 9. Shehata N, Austin T, Ha S, Timmerman K. Barriers to and facilitators of hepatitis C virus screening
432 and testing: A scoping review. *Can Commun Dis Rep.* 2018;44(7-8):166-72.
- 433 10. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV
434 infection: recommendations for a public health approach. Geneva: World Health Organization; 2016.
- 435 11. Jiang H, Xie Y, Xiong Y, Zhou Y, Lin K, Yan Y, et al. HIV self-testing partially filled the HIV testing gap
436 among men who have sex with men in China during the COVID-19 pandemic: results from an online
437 survey. *J Int AIDS Soc.* 2021;24(5):e25737.
- 438 12. Johnson CC, Kennedy C, Fonner V, Siegfried N, Figueroa C, Dalal S, et al. Examining the effects of
439 HIV self-testing compared to standard HIV testing services: a systematic review and meta-analysis. *J Int*
440 *AIDS Soc.* 2017;20(1):21594.
- 441 13. Wiktor S, Ford N, Ball A, Hirnschall G. HIV and HCV: distinct infections with important overlapping
442 challenges. *J Int AIDS Soc.* 2014;17:19323.

- 443 14. Recommendations and guidance on hepatitis C virus self-testing. Geneva: World Health
444 Organization; 2021.
- 445 15. Md Said R, Mohd Zain R, Chan HK, Soelar SA, Rusli N, Nasir NH, et al. Find the Missing Millions:
446 Malaysia's experience with nationwide hepatitis C screening campaign in the general population. *J Viral*
447 *Hepat.* 2020;27(6):638-43.
- 448 16. Markby J, Shilton S, Sem X, Chan HK, Said RM, Siva S, et al. Assessing the impact of simplified HCV
449 care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective
450 observational study. *BMJ Open.* 2021;11(12):e055142.
- 451 17. Chan H, Hassali MA, R. MS, R. AHM. Treatment Coverage and Drug Expenditure in Hepatitis C
452 Patients From 2013 to 2019: A Journey of Improving Treatment Accessibility in Malaysia Through
453 Government-led Initiatives. *Hepat Mon.* 2020;20(9):e107372.
- 454 18. Chan HK, Hassali MA, Md Said R, Omar H, Abd Mutalib NA, De Rozario FW, et al. A Two-Year
455 Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using
456 a Standard Two-Drug Regimen in Malaysia. *Hepat Mon.* 2021;21(3):e113226.
- 457 19. Nguyen LT, Nguyen VTT, Le Ai KA, Truong MB, Tran TTM, Jamil MS, et al. Acceptability and
458 Usability of HCV Self-Testing in High Risk Populations in Vietnam. *Diagnostics (Basel).* 2021;11(2).
- 459 20. Reipold EI, Farahat A, Elbeeh A, Soliman R, Aza EB, Jamil MS, et al. Usability and acceptability of
460 self-testing for hepatitis C virus infection among the general population in the Nile Delta region of Egypt.
461 *BMC Public Health.* 2021;21(1):1188.
- 462 21. Fajardo E, Watson V, Kumwenda M, Usharidze D, Gogochashvili S, Kakhaberi D, et al. Usability
463 and acceptability of oral-based HCV self-testing among key populations: a mixed-methods evaluation in
464 Tbilisi, Georgia. *BMC Infect Dis.* 2022;22(1):510.

- 465 22. Majam M, Fischer A, Ivanova Reipold E, Rhagnath N, Msolomba V, Lalla-Edward ST. A Lay-User
466 Assessment of Hepatitis C Virus Self-Testing Device Usability and Interpretation in Johannesburg, South
467 Africa. *Diagnostics (Basel)*. 2021;11(3).
- 468 23. Martinez-Perez GZ, Nikitin DS, Bessonova A, Fajardo E, Bessonov S, Shilton S. Values and
469 preferences for hepatitis C self-testing among people who inject drugs in Kyrgyzstan. *BMC Infect Dis*.
470 2021;21(1):609.
- 471 24. Serumondo J, Shilton S, Nshimiyimana L, Karame P, Dushimiyimana D, Fajardo E, et al. Values and
472 preferences for hepatitis C self-testing among the general population and healthcare workers in Rwanda.
473 *BMC Infect Dis*. 2021;21(1):1064.
- 474 25. Gwet KL. Computing inter-rater reliability and its variance in the presence of high agreement. *Br*
475 *J Math Stat Psychol*. 2008;61(1): 29-48.
- 476 26. Ho SY, Su LH, Sun HY, Huang YS, Chuang YC, Huang MH, et al. Trends of recent hepatitis C virus
477 infection among HIV-positive men who have sex with men in Taiwan, 2011-2018. *EClinicalMedicine*.
478 2020;24:100441.
- 479 27. Lockart I, Matthews GV, Danta M. Sexually transmitted hepatitis C infection: the evolving
480 epidemic in HIV-positive and HIV-negative MSM. *Curr Opin Infect Dis*. 2019;32(1):31-7.
- 481 28. Muhamad NA, Ab.Ghani RM, Abdul Mutalip MH, Muhammad EN. Seroprevalence of hepatitis B
482 virus and hepatitis C virus infection among Malaysian population. *Sci Rep*. 2020;10(21009).
- 483 29. Hassan MRA, Chan HK. Comment on: "Projections of the Healthcare Costs and Disease Burden
484 due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018-2040". *Appl Health Econ*
485 *Health Policy*. 2020;18(1):139-40.
- 486 30. Sun J, Cheng H, Hassan MRA, Chan HK, Piedagnel JM. What China can learn from Malaysia to
487 achieve the goal of "eliminate hepatitis C as a public health threat" by 2030 - a narrative review. *Lancet*
488 *Reg Health West Pac*. 2021;16:100261.

- 489 31. Catania JA, Huun C, Dolcini MM, Urban AJ, Fleury N, Ndyetabula C, et al. Overcoming cultural
490 barriers to implementing oral HIV self-testing with high fidelity among Tanzanian youth. *Transl Behav*
491 *Med.* 2021;11(1):87-95.
- 492 32. Wei C, Yan L, Li J, Su X, Lippman S, Yan H. Which user errors matter during HIV self-testing? A
493 qualitative participant observation study of men who have sex with men (MSM) in China. *BMC Public*
494 *Health.* 2018;18(1):1108.
- 495 33. Figueroa C, Johnson C, Ford N, Sands A, Dalal S, Meurant R, et al. Reliability of HIV rapid diagnostic
496 tests for self-testing compared with testing by health-care workers: a systematic review and meta-
497 analysis. *Lancet HIV.* 2018;5(6):e277-e90.
- 498 34. Blas MM, Alva IE, Carcamo CP, Cabello R, Goodreau SM, Kimball AM, et al. Effect of an online
499 video-based intervention to increase HIV testing in men who have sex with men in Peru. *PLoS One.*
500 2010;5(5):e10448.
- 501 35. Hawk ME, Chung A, Creasy SL, Egan JE. A Scoping Review of Patient Preferences for HIV Self-
502 Testing Services in the United States: Implications for Harm Reduction. *Patient Prefer Adherence.*
503 2020;14:2365-75.
- 504 36. Merchant RC, Clark MA, Liu T, Rosenberger JG, Romanoff J, Bauermeister J, et al. Preferences for
505 oral fluid rapid HIV self-testing among social media-using young black, Hispanic, and white men-who-
506 have-sex-with-men (YMSM): implications for future interventions. *Public Health.* 2017;145:7-19.
- 507 37. Gibson BA, Brown SE, Rutledge R, Wickersham JA, Kamarulzaman A, Altice FL. Gender identity,
508 healthcare access, and risk reduction among Malaysia's mak nyah community. *Glob Public Health.*
509 2016;11(7-8):1010-25.
- 510 38. Wait S, Kell E, Hamid S, Muljono DH, Sollano J, Mohamed R, et al. Hepatitis B and hepatitis C in
511 southeast and southern Asia: challenges for governments. *Lancet Gastroenterol Hepatol.* 2016;1(3):248-
512 55.

513 39. Shilton S, Sem X, Chan HK, Chung HY, Karunanithy A, Markby J, et al. A quasi-randomised
514 controlled trial of online distribution of home-based hepatitis C self-testing for key populations in
515 Malaysia: a study protocol. *Trials* 23, 304 (2022).

516


517

518 **Supporting information**

519 S1 Fig. **Contrived results for both the oral fluid- and blood-based tests.** ¹Positive (with clear
520 control and test lines); ²Weak positive (with a clear control line and a faint test line); ³Negative
521 (with only a clear control line); ⁴Invalid (without either control or test lines); ⁵Invalid (with only a
522 clear test line)

523

Figure 1: Flowchart of participant enrolment.



GP, general population; HCVST, hepatitis C self-testing; MSM, men who have sex with men.